Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact that a de facto annual review has had on drug approval timelines, and why a more streamlined and data driven review process is positive news for the innovative pharmaceutical industry. However, Bouteiller cautions that the race to the bottom … Continue reading China’s National Reimbursement Drug List (NRDL) 2020: What Reward for Innovation?